EGF THERAMED HEALTH Provides Update on Pharmadelic Labs and Green Parrot Labs

VANCOUVER, BC / ACCESSWIRE / July 20, 2020 /  EGF THERAMED HEALTH CORP. (CSE:TMED)(OTCQB:EVAHF)(FRA:AUHP) (the “Company“) announces that it will rely on the temporary relief granted pursuant to British Columbia Instrument 51-517 (Temporary Exemption from Certain Corporate Finance Requirements with Deadlines during the Period from June 2 to August 31, 2020) in respect of the filing of business acquisition reports (“BAR“) for its acquisition of a 30% equity interest in Pharmadelic Labs Corp. (“Pharmadelic“) on May 6, 2020 and its acquisition of a 40% equity interest in Green Parrot Labs Corp. (“Green Parrot“) on May 25, 2020. Based on the timeframe prescribed by National Instrument 51-102 (Continuous Disclosure Obligations), the BAR for the Pharmadelic transaction would be due on July 20, 2020 and the BAR for the Green Parrot transaction would be due on August 10, 2020. The BAR for the Pharmadelic transaction is now expected to be filed no later than September 3, 2020 and the BAR for the Green Parrot transaction is now expected to be filed no later than September 24, 2020.

FOR MORE INFORMATION PLEASE CONTACT:

EGF THERAMED HEALTH CORP.
Doug McFaul
Email: dmcfaul@emprisecapital.com
Telephone: (778) 331 8505
Website: http://www.theramedhealthcorp.com
CSE Micro-site: http://thecse.com/en/listings/technology/Theramed-Health-Corporation
US OTC Markets (OTCQB): http://www.otcmarkets.com/stock/EVAHF/news
Frankfurt Borse: https://www.boerse-frankfurt.de/equity/egf-theramed-health-corp

SOURCE: EGF Theramed Health Corp

View source version on accesswire.com:
https://www.accesswire.com/598195/EGF-THERAMED-HEALTH-Provides-Update-on-Pharmadelic-Labs-and-Green-Parrot-Labs

Staff

Recent Posts

Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis

Clinical trial infrastructure fully operational in the U.S. with more than 15 leading cardiovascular centers…

17 minutes ago

CannaPharmaRX Provides Corporate Update and Outlines Growth Strategy for 2026

CALGARY, AB / ACCESS Newswire / January 12, 2026 / CannaPharmaRX, Inc. (OTC PINK:CPMD), an…

11 hours ago

TempraMed Closes C$2.5 Million Fully Subscribed Private Placement

Vancouver, British Columbia--(Newsfile Corp. - January 12, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE:…

14 hours ago

TruuCONNECT NJ Statewide Digital Hub Empowers Users to Find Verified, Local Community Resources and Support – Anonymously and in Real Time

MOUNT LAUREL, N.J., Jan. 12, 2026 /PRNewswire/ -- Born out of a partnership between the…

14 hours ago

Nuvo Unveils Large-Scale AI-Ready Pregnancy Dataset Built on Real-World Maternal and Fetal Physiology

Unique longitudinal dataset combining native fetal and maternal ECG with phonocardiography supports deeper insights into…

14 hours ago

Alamar Biosciences Announces Launch of NULISAqpcr™ AD 5-plex Assay, Advancing Blood Based Biomarker Detection in Alzheimer’s Disease Research

FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision…

14 hours ago